Sharma Arun, Sinha Mumun, Pandey Niraj Nirmal, Chandrashekhara S H
Department of Cardiovascular Radiology and Endovascular Interventions, All India Institute of Medical Sciences, New Delhi, India.
Department of Radiodiagnosis, BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.
Indian J Radiol Imaging. 2019 Oct-Dec;29(4):397-403. doi: 10.4103/ijri.IJRI_385_19. Epub 2019 Dec 31.
Critical limb ischemia (CLI) represents the most severe manifestation of peripheral arterial disease (PAD). It imposes a huge economic burden and is associated with high short-term mortality and adverse cardiovascular outcomes. Prompt recognition and early revascularization, surgical or endovascular, with the aim of improving the inline bloodflow to the ischemic limb, are currently the standard of care. However, this strategy may not always be feasible or effective; hence, evaluation of newer pharmacological or angiogenic therapies for alleviating the symptoms of this alarming condition is of utmost importance. Cell-based therapies have shown promise in smaller studies; however, large-scale studies, demonstrating definite survival benefits, are entailed to ascertain their role in the management of CLI.
严重肢体缺血（CLI）是外周动脉疾病（PAD）最严重的表现形式。它带来了巨大的经济负担，且与高短期死亡率及不良心血管结局相关。目前，以改善缺血肢体的顺行血流为目标，迅速识别并尽早进行外科或血管内血运重建是标准治疗方法。然而，这一策略并非总是可行或有效的；因此，评估用于缓解这种严重疾病症状的新型药物或血管生成疗法至关重要。在规模较小的研究中，基于细胞的疗法已显示出前景；然而，需要大规模研究来证实其在CLI治疗中的作用，以明确其对生存的益处。
